论文部分内容阅读
经内镜确诊的６９例十二指肠溃疡病病人，随机分为尼扎替丁组（３７例）和雷尼替丁组（３２例），两种药物剂量均为每晚３００ｍｇ口服，疗程４ｗｋ或８ｗｋ。尼扎替丁和雷尼替丁的溃疡愈合率４ｗｋ分别为９７．３％和９６．９％，８ｗｋ均为１００％，两组间无显著性差异（Ｐ＞０．０５）。但对疼痛的缓解，无论是治疗后３ｄ，１ｗｋ及２ｗｋ的疼痛缓解率，尼扎替丁组明显高于雷尼替丁组（Ｐ＜０．０５）。治疗中两种药物均无严重不良反应。因此，尼扎替丁是一个新的治疗十二指肠溃疡病的安全有效的Ｈ２受体阻断药。
Ninety-nine patients with duodenal ulcer diagnosed by endoscopy were randomly divided into nizatidine group (n = 37) and ranitidine group (n = 32). The doses of the two drugs were 300 mg per night orally. The course of treatment 4wk or 8wk. The healing rates of nizatidine and ranitidine were 97.3% and 96.9% for 4wk and 100% for 8wk, respectively. There was no significant difference between the two groups (P> 0.05). However, pain relief, no matter 3d, 1wk and 2wk after pain relief, nizatidine group was significantly higher than ranitidine group (P <0.05). No serious adverse reactions to both drugs in the treatment. Therefore, nizatidine is a new safe and effective H2 receptor blocker for the treatment of duodenal ulcer disease.